POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.12.2021, 3:33pm CEST, WHO):   U.S. 13,304    India 84,332    Brazil 88,092    France 3,639    Turkey 6,261    Russia 13,510    The United Kingdom 7,958    Italy 1,892    Argentina 27,628    Germany 1,911    Columbia 29,302    Iran 9,966    Mexico 3,672    Ukraine 1,274    Peru 4,054    Indonesia 8,083    South Africa 8,020    The Netherlands 1,417    Chile 7,941    Canada 1,476    Philippines 6,686    Iraq 4,320    Pakistan 1,303    Bangladesh 2,454    Japan 1,920    Malaysia 6,849    Nepal 2,709    United Arab Emirates 2,281    Saudi Arabia 1,175    Ecuador 1,098    Belarus 1,026    Bolivia 3,233    Paraguay 2,758    Tunisia 2,161    Costa Rica 2,041    Uruguay 3,622    Kuwait 1,657    Dominican Republic 1,129    Guatemala 1,861    Venezuela 1,083    Sri Lanka 2,789    Thailand 3,277    Cuba 1,288    Zambia 2,065    Afghanistan 1,024    Mongolia 1,622    Namibia 1,432    Botswana 1,392    Uganda 1,566    China 322    Singapore 9    New Zealand 0    Australia 3    South Korea 565   

Trials for AstraZeneca's coronavirus treatment set to begin in UK

Christian Fernsby |
The UK will be the first country to begin clinical trials of a new coronavirus antibody treatment developed by drugs giant AstraZeneca PLC aimed at people with a weakened immune system who cannot be vaccinated.

Article continues below




A participant in Manchester will be the first in the world to receive the pharmaceutical company's new "antibody cocktail" as part of the trial to test whether it will prevent Covid-19 for up to year.

The clinical trial programme will recruit 5,000 participants, which includes 1,000 people from nine sites in the UK.

The aim of the trial is to evaluate the safety and effectiveness of a combination of two long-acting monoclonal antibodies man made proteins that act like natural human antibodies in the immune system.


What to read next

Biopsies during early treatment predict response to melanoma immunotherapy
Pig trial of AstraZeneca's coronavirus vaccine shows promise with two shots
Three-minute brain stimulation therapy effective for hard-to-treat depression